Literature DB >> 11681657

Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.

Y S Cheng1, C S Fu, D Yazzie, Y Zhou.   

Abstract

This paper describes a technique that uses a well-defined human airway replica and gamma counting as a standard method for evaluating and comparing the performance of medical inhalers and spacers. High-fidelity replicas reproduced as needed from master casts made from human cadavers include the oropharyngeal cavity, larynx, trachea, and five to nine generations of bronchi. Deposition in the small airways and alveoli region of the cast is simulated by material that passes through the upstream airways and is collected on foam filters. Deposition patterns in the respiratory tract replica were obtained by using radiolabel in the medical inhaler and by gamma scintigraphy. This technique was used to determine respiratory deposition patterns of salbutamol in a pressurized metered dose inhaler (pMDI) with chlorofluorocarbon (CFC, in-house formulation) and HFA-134 formulations (Proventil hydrofluoroalkane [HFA]). At an inspiration flow of 30 L/min, patterns in the salbutamol/CFC formula showed a high deposition in the oropharyngeal airway (78%) and a 16% deposition in the lung, similar to in vivo measurements reported in the literature. However, the salbutamol/HFA formula showed lower oral deposition (56%) but higher lung deposition (24%). The difference in the oral deposition patterns may be attributed to lower initial spray velocity, initial droplet evaporation rate, and possibly initial droplet sizes of Proventil HFA. The small orifice diameter (0.25 mm) of the Proventil HFA actuator produced a softer plume with a smaller impact force, resulting in lower oropharyngeal deposition. Cascade impactor measurements showed similar aerodynamic particle size distribution of the CFC and HFA formulations. We also showed that using spacers in the Proventil HFA resulted in a lower oropharyngeal deposition and higher lung deposition, indicating beneficial effects. Comparison of oropharyngeal deposition and those predicted by artificial throats used in the impactor measurements showed that, in general, the artificial throat predicted a lower deposition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11681657     DOI: 10.1089/08942680152484180

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  23 in total

1.  Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model.

Authors:  Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2010-05-08       Impact factor: 4.200

2.  Multimodal particle size distributions emitted from HFA-134a solution pressurized metered-dose inhalers.

Authors:  Hugh D C Smyth; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

3.  Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental results.

Authors:  P Worth Longest; Michael Hindle
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

4.  Characterization of Nanoaerosol Size Change During Enhanced Condensational Growth.

Authors:  P Worth Longest; James T McLeskey; Michael Hindle
Journal:  Aerosol Sci Technol       Date:  2010-06-01       Impact factor: 2.908

5.  Feasibility of tissue plasminogen activator formulated for pulmonary delivery.

Authors:  John S Dunn; Rajiv Nayar; Jackie Campos; Brooks M Hybertson; Yue Zhou; Mark Cornell Manning; John E Repine; Kathleen A Stringer
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

6.  Effect of oropharyngeal length in drug lung delivery via suspension pressurized metered dose inhalers.

Authors:  T Ehtezazi; D R Allanson; I D Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

7.  Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.

Authors:  Rajoshi Biswas; Nicola A Hanania; Ashutosh Sabharwal
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-02-03       Impact factor: 2.849

8.  Comparison of deposition in the USP and physical mouth-throat models with solid and liquid particles.

Authors:  Yue Zhou; Jaijie Sun; Yung-Sung Cheng
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-07-06       Impact factor: 2.849

9.  Effect of Inhalation Flow Rate on Mass-Based Plume Geometry of Commercially Available Suspension pMDIs.

Authors:  Daniel F Moraga-Espinoza; Eli Eshaghian; Albert Shaver; Hugh D C Smyth
Journal:  AAPS J       Date:  2018-07-12       Impact factor: 4.009

10.  Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

Authors:  Geng Tian; P Worth Longest; Xiang Li; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-01-03       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.